Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

Part of paid clinical trials in Stanford, California.

Sponsor
Miltenyi Biomedicine GmbH
Study ID
NCT06116110
Status
Recruiting
Apply to this trial

Conditions

  • Non Hodgkin Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Long-term Follow-Up — OTHER
    No intervention

Study Details

This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.

Key Dates

Start date
May 15, 2024
Status verified
Nov 2024
Primary completion
Dec 1, 2039
Completion
Dec 1, 2039

Study Design

Enrollment
150 participants (estimated)

Arms

  • Arm: Long-term Follow-Up
    No intervention

Primary Outcome Measure

The incidence of serious and non serious adverse events of special interest [ Time Frame: Up to 15 years ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Stanford UniversityStanfordCalifornia94305
Christina Tran
[email protected]
Yale UniversityNew HavenConnecticut06520
Jialing Zhang
[email protected]
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer CenterBaltimoreMaryland21201
Nancy Hardy, MD
[email protected]
Dana Farber Cancer InstituteBostonMassachusetts02215
Christopher Simmons
[email protected]
Froedtert Hospital and the Medical College of WisconsinMilwaukeeWisconsin53226
Hailey McArthey
[email protected]

Find similar trials in Stanford, CA

By research site
Stanford University· Stanford, CAYale University· New Haven, CTUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center· Baltimore, MDDana Farber Cancer Institute· Boston, MAFroedtert Hospital and the Medical College of Wisconsin· Milwaukee, WI

Related Studies